Review
doi: 10.1016/s1059-1311(05)80076-7.
Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options
Affiliations
- PMID: 7788105
- DOI: 10.1016/s1059-1311(05)80076-7
Item in Clipboard
Review
Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options
Seizure.
1995 Mar.
Free article
Abstract
A pharmaco-economic study of the administration of adjunctive therapy in patients with chronic epilepsy is described. A decision-analytic model has been used, which represents the consequences of treatment over a 1-year time period, when one of three drugs is used first. The cost-effectiveness ratio for clobazam, lamotrigine and vigabatrin have been calculated. The expected cost per patient of treatment over the 1-year period was up to 50% higher with vigabatrin and lamotrigine compared with clobazam, with a cost-effectiveness ratio around 40% higher.
Similar articles
-
If comparisons can be odious, so can assumptions.Seizure. 1996 Sep;5(3):247-8. doi: 10.1016/s1059-1311(96)80045-8. Seizure. 1996. PMID: 8902930 No abstract available.
-
New anti-epileptic drugs in the 1990s.J Paediatr Child Health. 1994 Aug;30(4):298-300. doi: 10.1111/j.1440-1754.1994.tb00649.x. J Paediatr Child Health. 1994. PMID: 7946538 Review. No abstract available.
-
A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy.Seizure. 1996 Jun;5(2):89-95. doi: 10.1016/s1059-1311(96)80100-2. Seizure. 1996. PMID: 8795122 Review.
-
Costing of antiepileptic drugs.Lancet. 1996 Jan 27;347(8996):266. doi: 10.1016/s0140-6736(96)90443-2. Lancet. 1996. PMID: 8551913 No abstract available.
-
Adjunctive therapy in epilepsy with new antiepileptic drugs: is it of any value?Seizure. 1998 Oct;7(5):417-8. doi: 10.1016/s1059-1311(05)80014-7. Seizure. 1998. PMID: 9808121 Clinical Trial.
Cited by
-
The cost effectiveness of newer epilepsy treatments: a review of the literature on partial-onset seizures.Pharmacoeconomics. 2012 Oct 1;30(10):903-23. doi: 10.2165/11597110-000000000-00000. Pharmacoeconomics. 2012. PMID: 22924967 Review.
-
Assessment of components included in published societal perspective or QALY outcome economic analyses for antiepileptic drug treatment in chronic epilepsy.Expert Rev Pharmacoecon Outcomes Res. 2018 Oct;18(5):487-503. doi: 10.1080/14737167.2018.1489243. Epub 2018 Jun 28. Expert Rev Pharmacoecon Outcomes Res. 2018. PMID: 29911955 Free PMC article. Review.
-
The costs of epilepsy and cost-based evaluations of anticonvulsants.Pharmacoeconomics. 1997 Oct;12(4):446-59. doi: 10.2165/00019053-199712040-00003. Pharmacoeconomics. 1997. PMID: 10174311 Review.
-
Prescribing antiepileptic drugs: should patients be switched on the basis of cost?CNS Drugs. 2004;18(10):617-28. doi: 10.2165/00023210-200418100-00001. CNS Drugs. 2004. PMID: 15270592 Review.
-
Economic analysis of newer antiepileptic drugs.CNS Drugs. 2008;22(10):861-75. doi: 10.2165/00023210-200822100-00006. CNS Drugs. 2008. PMID: 18788837
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
